BACKGROUND: An association between early CD4+ T cell immune reconstitution (CD4+ IR) and survival after T-replete allogeneic hematopoietic cell transplantation (HCT) has been previously reported. Here we report validation of this relationship in a separate cohort that included recipients of ex vivo T-cell-depleted (TCD) HCT. We studied the relationship between CD4+ IR and clinical outcomes. METHODS: A retrospective analysis of children/young adults receiving their first allogeneic HCT for any indication between January 2008 and December 2017 was performed. We related early CD4+ IR (defined as achieving >50 CD4+ T cells/µL on two consecutive measures within 100 days of HCT) to overall survival (OS), relapse, non-relapse mortality (NRM), event-free survival (EFS) and acute graft-versus-host disease (aGVHD). Fine and Gray competing risk models and Cox proportional hazard models were used. RESULTS: In this analysis, 315 patients with a median age of 10.4 years (interquartile range 5.0-16.5 years) were included. The cumulative incidence of CD4+ IR at 100 days was 66.7% in the entire cohort, 54.7% in TCD (N = 208, hazard ratio [HR] 0.47, P < 0.001), 90.0% in uCB (N = 40) and 89.6% in T-replete (N = 47) HCT recipients. In multi-variate analyses, not achieving early CD4+ IR was a predictor of inferior OS (HR 2.35, 95% confidence interval [CI] 1.46-3.79, P < 0.001) and EFS (HR 1.80, 95% CI 1.20-2.69, P = 0.004) and increased NRM (HR 6.58, 95% CI 2.82-15.38, P < 0.001). No impact of CD4+ IR on relapse or aGVHD was found. Within the TCD group, similar associations were observed. CONCLUSION: In this HCT cohort, including recipients of TCD HCT, we confirmed that early CD4+ IR was an excellent predictor of outcomes. Finding strategies to predict or improve CD4+ IR may influence outcomes.
BACKGROUND: An association between early CD4+ T cell immune reconstitution (CD4+ IR) and survival after T-replete allogeneic hematopoietic cell transplantation (HCT) has been previously reported. Here we report validation of this relationship in a separate cohort that included recipients of ex vivo T-cell-depleted (TCD) HCT. We studied the relationship between CD4+ IR and clinical outcomes. METHODS: A retrospective analysis of children/young adults receiving their first allogeneic HCT for any indication between January 2008 and December 2017 was performed. We related early CD4+ IR (defined as achieving >50 CD4+ T cells/µL on two consecutive measures within 100 days of HCT) to overall survival (OS), relapse, non-relapse mortality (NRM), event-free survival (EFS) and acute graft-versus-host disease (aGVHD). Fine and Gray competing risk models and Cox proportional hazard models were used. RESULTS: In this analysis, 315 patients with a median age of 10.4 years (interquartile range 5.0-16.5 years) were included. The cumulative incidence of CD4+ IR at 100 days was 66.7% in the entire cohort, 54.7% in TCD (N = 208, hazard ratio [HR] 0.47, P < 0.001), 90.0% in uCB (N = 40) and 89.6% in T-replete (N = 47) HCT recipients. In multi-variate analyses, not achieving early CD4+ IR was a predictor of inferior OS (HR 2.35, 95% confidence interval [CI] 1.46-3.79, P < 0.001) and EFS (HR 1.80, 95% CI 1.20-2.69, P = 0.004) and increased NRM (HR 6.58, 95% CI 2.82-15.38, P < 0.001). No impact of CD4+ IR on relapse or aGVHD was found. Within the TCD group, similar associations were observed. CONCLUSION: In this HCT cohort, including recipients of TCD HCT, we confirmed that early CD4+ IR was an excellent predictor of outcomes. Finding strategies to predict or improve CD4+ IR may influence outcomes.
Authors: Dong Hwan Kim; Jong Gwang Kim; Sang Kyun Sohn; Woo Jin Sung; Jang Soo Suh; Kun Soo Lee; Kyu Bo Lee Journal: Br J Haematol Date: 2004-04 Impact factor: 6.998
Authors: Coco de Koning; Jurgen Langenhorst; Charlotte van Kesteren; Caroline A Lindemans; Alwin D R Huitema; Stefan Nierkens; Jaap Jan Boelens Journal: Biol Blood Marrow Transplant Date: 2018-10-23 Impact factor: 5.742
Authors: Rick Admiraal; Charlotte van Kesteren; Cornelia M Jol-van der Zijde; Arjan C Lankester; Marc B Bierings; Toine C G Egberts; Maarten J D van Tol; Catherijne A J Knibbe; Robbert G M Bredius; Jaap J Boelens Journal: Lancet Haematol Date: 2015-04-21 Impact factor: 18.959
Authors: Caron A Jacobson; Amin T Turki; Sean M McDonough; Kristen E Stevenson; Haesook T Kim; Grace Kao; Maria I Herrera; Carol G Reynolds; Edwin P Alyea; Vincent T Ho; John Koreth; Philippe Armand; Yi-Bin Chen; Karen Ballen; Robert J Soiffer; Joseph H Antin; Corey S Cutler; Jerome Ritz Journal: Biol Blood Marrow Transplant Date: 2011-08-26 Impact factor: 5.742
Authors: Rick Admiraal; Coco C H de Koning; Caroline A Lindemans; Marc B Bierings; Annemarie M J Wensing; A Birgitta Versluys; Tom F W Wolfs; Stefan Nierkens; Jaap Jan Boelens Journal: J Allergy Clin Immunol Date: 2017-04-07 Impact factor: 10.793
Authors: Benjamin R Oshrine; Yimei Li; David T Teachey; Jennifer Heimall; David M Barrett; Nancy Bunin Journal: Biol Blood Marrow Transplant Date: 2013-08-11 Impact factor: 5.742
Authors: Vanessa A Fabrizio; M Irene Rodriguez-Sanchez; Audrey Mauguen; Parastoo B Dahi; Ekaterina Doubrovina; Richard J O'Reilly; Susan E Prockop Journal: Blood Adv Date: 2021-01-26
Authors: Jiayu Wang; Meng Yuan; Guanghua Zhu; Runhui Wu; Chenguang Jia; Bin Wang; Jie Zheng; Jie Ma; Maoquan Qin; Sidan Li Journal: Int J Med Sci Date: 2022-05-01 Impact factor: 3.642
Authors: Coco de Koning; Susan Prockop; Ichelle van Roessel; Nancy Kernan; Elizabeth Klein; Jurgen Langenhorst; Celina Szanto; Mirjam Belderbos; Marc Bierings; Farid Boulad; Dorine Bresters; Maria Cancio; Kevin Curran; Wouter Kollen; Richard O'Reilly; Andromachi Scaradavou; Barbara Spitzer; Birgitta Versluijs; Alwin Huitema; Caroline Lindemans; Stefan Nierkens; Jaap Jan Boelens Journal: Blood Date: 2021-02-11 Impact factor: 22.113
Authors: Oriana Miltiadous; Nicholas R Waters; Hana Andrlová; Anqi Dai; Chi L Nguyen; Marina Burgos da Silva; Sarah Lindner; John Slingerland; Paul Giardina; Annelie Clurman; Gabriel K Armijo; Antonio L C Gomes; Madhavi Lakkaraja; Peter Maslak; Michael Scordo; Roni Shouval; Anna Staffas; Richard O'Reilly; Ying Taur; Susan Prockop; Jaap Jan Boelens; Sergio Giralt; Miguel-Angel Perales; Sean M Devlin; Jonathan U Peled; Kate A Markey; Marcel R M van den Brink Journal: Blood Date: 2022-05-05 Impact factor: 25.476
Authors: Anke Janssen; Eline van Diest; Anna Vyborova; Lenneke Schrier; Anke Bruns; Zsolt Sebestyen; Trudy Straetemans; Moniek de Witte; Jürgen Kuball Journal: Viruses Date: 2022-01-10 Impact factor: 5.048
Authors: Coco de Koning; Weiyang Tao; Amelia Lacna; Karin van Veghel; Mitchell E Horwitz; Guillermo Sanz; Madan H Jagasia; John E Wagner; Patrick J Stiff; Rabi Hanna; Daniela Cilloni; David Valcárcel; Tony Peled; Einat Galamidi Cohen; Uri Goshen; Aridaman Pandit; Caroline A Lindemans; Jaap Jan Boelens; Stefan Nierkens Journal: Bone Marrow Transplant Date: 2021-07-26 Impact factor: 5.174